Exploration of Prolonged Remission and the Natural Course of Cluster Headache: An Interview-Based Cohort Study.

IF 7.7 1区 医学 Q1 CLINICAL NEUROLOGY
Neurology Pub Date : 2025-07-01 Epub Date: 2025-06-13 DOI:10.1212/WNL.0000000000213795
Willemijn Naber, Paulien van Tilborg, Anna Zuidgeest, Leopoldine Wilbrink, Wim Mulleners, Roemer Brandt, Rolf Fronczek
{"title":"Exploration of Prolonged Remission and the Natural Course of Cluster Headache: An Interview-Based Cohort Study.","authors":"Willemijn Naber, Paulien van Tilborg, Anna Zuidgeest, Leopoldine Wilbrink, Wim Mulleners, Roemer Brandt, Rolf Fronczek","doi":"10.1212/WNL.0000000000213795","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>The aim of this study was to gain rare insight into prolonged cluster headache (CH) remission by (1) identifying patterns and factors associated with and (2) phenotypical changes before prolonged remission. The results can help patients better understand their disease course and uncover mechanisms behind spontaneous remission.</p><p><strong>Methods: </strong>In this cross-sectional cohort study, all participants with a history of (probable) CH from the Leiden University Medical Center cohort were invited to complete a screening survey. Participants in prolonged remission were invited for a telephone interview. Prolonged remission was defined as (1) no current prophylactic treatment and (2) an attack-free period of ≥5 years and/or twice the mean between-episode time. Main outcomes are average age at prolonged remission onset and disease duration. Data were collected between April 10 and August 9, 2024, and analyzed using descriptive and survival statistics.</p><p><strong>Results: </strong>Of those invited, 43.2% (778/1,801) responded; 625 were included in the survey analysis, and 125 (20%) met prolonged remission criteria during interview. The median age at inclusion was 58 years (interquartile range [IQR] 48-67) with 32% female. Remission occurred on average at age 55 (IQR 48-63) after a disease duration of 23 (15-33) years. In 62% (N = 78), remission occurred abruptly. Of those with gradual remission (38%, N = 47), attack frequency (65%) and intensity (59%) decreased and between-episode intervals increased (52%) before remission. Probability of prolonged remission was higher in those with episodic CH (hazard ratio [HR] 6.60, 95% CI 3.55-12.31), who had quit smoking (HR 2.53, 95% CI 1.66-3.86), who had a higher attack intensity (HR 1.28, 95% CI 1.08-1.52), and who had a higher age at disease onset (HR 1.05, 95% CI 1.03-1.06).</p><p><strong>Discussion: </strong>This cohort offers rare insight into prolonged CH remission, typically starting around the mid-50s after 25 years of active disease. Prolonged remission is not tied to a single factor such as disease duration. Remission onset does not peak at a specific age, and disease duration varies widely between patients with remission. Remission probability is higher in the episodic form despite a longer disease duration compared with the chronic form. The association between quitting smoking and prolonged remission supports a causal link with smoking and disease activity. These preliminary retrospective results require confirmation in future studies.</p>","PeriodicalId":19256,"journal":{"name":"Neurology","volume":"105 1","pages":"e213795"},"PeriodicalIF":7.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172058/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/WNL.0000000000213795","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objectives: The aim of this study was to gain rare insight into prolonged cluster headache (CH) remission by (1) identifying patterns and factors associated with and (2) phenotypical changes before prolonged remission. The results can help patients better understand their disease course and uncover mechanisms behind spontaneous remission.

Methods: In this cross-sectional cohort study, all participants with a history of (probable) CH from the Leiden University Medical Center cohort were invited to complete a screening survey. Participants in prolonged remission were invited for a telephone interview. Prolonged remission was defined as (1) no current prophylactic treatment and (2) an attack-free period of ≥5 years and/or twice the mean between-episode time. Main outcomes are average age at prolonged remission onset and disease duration. Data were collected between April 10 and August 9, 2024, and analyzed using descriptive and survival statistics.

Results: Of those invited, 43.2% (778/1,801) responded; 625 were included in the survey analysis, and 125 (20%) met prolonged remission criteria during interview. The median age at inclusion was 58 years (interquartile range [IQR] 48-67) with 32% female. Remission occurred on average at age 55 (IQR 48-63) after a disease duration of 23 (15-33) years. In 62% (N = 78), remission occurred abruptly. Of those with gradual remission (38%, N = 47), attack frequency (65%) and intensity (59%) decreased and between-episode intervals increased (52%) before remission. Probability of prolonged remission was higher in those with episodic CH (hazard ratio [HR] 6.60, 95% CI 3.55-12.31), who had quit smoking (HR 2.53, 95% CI 1.66-3.86), who had a higher attack intensity (HR 1.28, 95% CI 1.08-1.52), and who had a higher age at disease onset (HR 1.05, 95% CI 1.03-1.06).

Discussion: This cohort offers rare insight into prolonged CH remission, typically starting around the mid-50s after 25 years of active disease. Prolonged remission is not tied to a single factor such as disease duration. Remission onset does not peak at a specific age, and disease duration varies widely between patients with remission. Remission probability is higher in the episodic form despite a longer disease duration compared with the chronic form. The association between quitting smoking and prolonged remission supports a causal link with smoking and disease activity. These preliminary retrospective results require confirmation in future studies.

丛集性头痛的长期缓解和自然病程的探讨:一项基于访谈的队列研究。
背景和目的:本研究的目的是通过(1)确定与慢性丛集性头痛(CH)缓解相关的模式和因素以及(2)延长缓解前的表型变化来获得罕见的见解。结果可以帮助患者更好地了解他们的疾病过程,并揭示自发缓解背后的机制。方法:在这项横断面队列研究中,莱顿大学医学中心队列中所有有(可能)CH病史的参与者被邀请完成筛查调查。长期缓解的参与者被邀请进行电话采访。延长缓解被定义为(1)目前没有预防性治疗,(2)无发作期≥5年和/或平均发作间隔时间的两倍。主要转归是缓解期延长时的平均年龄和疾病持续时间。数据收集于2024年4月10日至8月9日,并使用描述性和生存统计进行分析。结果:在受邀者中,有43.2%(778/ 1801)回复;625例纳入调查分析,125例(20%)在访谈中符合延长缓解标准。纳入时的中位年龄为58岁(四分位数范围[IQR] 48-67),其中32%为女性。病程23(15-33)年,平均在55岁(IQR 48-63)时出现缓解。62% (N = 78)患者的缓解是突然发生的。在逐渐缓解的患者中(38%,N = 47),缓解前发作频率(65%)和强度(59%)下降,发作间隔(52%)增加。发作性慢性阻塞性肺病患者(危险比[HR] 6.60, 95% CI 3.55-12.31)、戒烟者(危险比[HR] 2.53, 95% CI 1.66-3.86)、发作强度较高的患者(危险比[HR] 1.28, 95% CI 1.08-1.52)、发病年龄较高的患者(危险比[HR] 1.05, 95% CI 1.03-1.06)延长缓解的可能性较高。讨论:该队列提供了罕见的长期CH缓解的见解,通常在25年的活动性疾病后开始于55岁左右。延长缓解期与疾病持续时间等单一因素无关。缓解期的发作并不是在特定的年龄达到高峰,缓解期患者的病程也有很大的不同。与慢性形式相比,发作形式的缓解概率更高,尽管病程较长。戒烟和长期缓解之间的联系支持了吸烟和疾病活动之间的因果关系。这些初步的回顾性结果需要在未来的研究中得到证实。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurology
Neurology 医学-临床神经学
CiteScore
12.20
自引率
4.00%
发文量
1973
审稿时长
2-3 weeks
期刊介绍: Neurology, the official journal of the American Academy of Neurology, aspires to be the premier peer-reviewed journal for clinical neurology research. Its mission is to publish exceptional peer-reviewed original research articles, editorials, and reviews to improve patient care, education, clinical research, and professionalism in neurology. As the leading clinical neurology journal worldwide, Neurology targets physicians specializing in nervous system diseases and conditions. It aims to advance the field by presenting new basic and clinical research that influences neurological practice. The journal is a leading source of cutting-edge, peer-reviewed information for the neurology community worldwide. Editorial content includes Research, Clinical/Scientific Notes, Views, Historical Neurology, NeuroImages, Humanities, Letters, and position papers from the American Academy of Neurology. The online version is considered the definitive version, encompassing all available content. Neurology is indexed in prestigious databases such as MEDLINE/PubMed, Embase, Scopus, Biological Abstracts®, PsycINFO®, Current Contents®, Web of Science®, CrossRef, and Google Scholar.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信